HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments

Executive Summary

While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.

You may also be interested in...



Sun Setting On Attempts To Expand Hawaii Sunscreen Ingredient Ban During 2021

Advocates hoped a study suggesting octocrylene in sunscreens may degrade into benzophenone would convince lawmakers to expand ban, but a House committee maintained its commitment to wait on more research.

Cruelty Free Europe Grieves: ‘Very Little Left Now’ Of Cosmetic Animal-Testing Bans

The European Chemicals Agency's Board of Appeal finds that REACH requires ingredient registrants to perform animal studies, even if their substances are used exclusively in cosmetic products. Historically opposed industry and animal welfare groups both may lose under the board’s decisions.

EU Scientific Committee Reviewing Three UV Filters Against Endocrine-Disrupting Concerns

The European Commission issued requests on 4 February for updated opinions from the Scientific Committee on Consumer Safety on octocrylene, homosalate and benzophenone-3, in light of concerns that led to their listing in 2019 as “higher priority” substances used in cosmetics with endocrine-disrupting potential.

Topics

UsernamePublicRestriction

Register

RS150926

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel